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Abstract
Melatonin and resistance exercise alone have been shown to increase the levels of growth
hormone (GH). The purpose of this study was to determine the effects of ingestion of a single dose
of melatonin and heavy resistance exercise on serum GH, somatostatin (SST), and other hormones
of the GH/insulin-like growth factor 1 (IGF-1) axis. Physically active males (n = 30) and females (n
= 30) were randomly assigned to ingest either a melatonin supplement at 0.5 mg or 5.0 mg, or 1.0
mg of dextrose placebo. After a baseline blood sample, participants ingested the supplement and
underwent blood sampling every 15 min for 60 min, at which point they underwent a single bout
of resistance exercise with the leg press for 7 sets of 7 reps at 85% 1-RM. After exercise,
participants provided additional blood samples every 15 min for a total of 120 min. Serum free GH,
SST, IGF-1, IGFBP-1, and IGFBP-3 were determined with ELISA. Data were evaluated as the peak
pre- and post-exercise values subtracted from baseline and the delta values analyzed with separate
three-way ANOVA (p < 0.05). In males, when compared to placebo, 5.0 mg melatonin caused GH
to increase (p = 0.017) and SST to decrease prior to exercise (p = 0.031), whereas both 0.5 and
5.0 mg melatonin were greater than placebo after exercise (p = 0.045) and less than placebo for
SST. No significant differences occurred for IGF-1; however, males were shown to have higher
levels of IGFBP-1 independent of supplementation (p = 0.004). The 5.0 mg melatonin dose resulted
in higher IGFBP-3 in males (p = 0.017). In conclusion, for males 5.0 mg melatonin appears to
increase serum GH while concomitantly lowering SST levels; however, when combined with
resistance exercise both melatonin doses positively impacts GH levels in a manner not entirely
dependent on SST.
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Background
Growth hormone is secreted from the adenohypohysis of
the pituitary gland and is regulated by a final common
pathway, consisting of inhibitory control of somatostatin
(SST) and stimulatory control of hypothalamic GH-
releasing hormone (GHRH). As such, GH is known to dis-
play profound anabolic effects at the tissue level and has
been implicated to play a significant role in metabolic reg-
ulation, protein synthesis, and cell multiplication and dif-
ferentiation in skeletal muscle. Once secreted into the
circulation, free, unbound GH has a half-life of approxi-
mately nine minutes [1]. Almost 50% of GH in circulation
is bound to a high-affinity GH binding protein (GHBP),
and GHBP seems to directly correlate with tissue GH
receptor content [2]. However, it is the free, unbound GH
that is able to bind to the extracellular domain of the GH
receptor, thereby effecting GH kinetics which can invaria-
bly regulate growth factor release and GH signaling in
skeletal muscle. Relative to skeletal muscle, the anabolic
role of GH is based on the circulating levels of free GH and
exists due to its influence on the activity of various growth
factors such as insulin-like growth factor 1 (IGF-1).
The majority of GH secretion from the pituitary is control-
led by hormonal signals received from the hypothalamus.
In addition, GH release can also be regulated at the
hypothalamic level by various metabolic stress signals
such as acute resistance exercise. The release of GH has
been shown to occur in response to single bouts of resist-
ance exercise. A single bout of resistance exercise at 85%
of the one-repetition maximum (1-RM) was shown to sig-
nificantly elevate serum GH [3]. Also, when compared to
a single set of high-intensity resistance exercise at 90% 1-
RM, a single set of low- and moderate-intensity resistance
exercise at either 50% or 70% 1-RM immediately follow-
ing high intensity exercise resistance exercise at 90% 1-RM
produced greater increases in serum GH levels [4]. These
data suggest that a high intensity, low volume training
protocol known to typically induce neural adaptation
does not result in a serum GH response commensurate
with those observed to occur with low- to moderate-inten-
sity resistance exercise.
The indolamine melatonin (N-Acetyl-5-methoxytryp-
tamine) is a lipophilic hormone synthesized by the pineal
gland and has been shown to be involved in hormone
release [5]. As such, melatonin has been shown to play a
facilitatory role in the neuroregulation of growth hor-
mone (GH) secretion at the hypothalamic level, evi-
denced by peak elevations in serum GH in males 60 min
after the acute oral ingestion of melatonin at doses of 500
mg [6] and 12 mg [7]. It has been suggested that the mech-
anism for melatonin's neuroregulatory role is through the
binding of meltatonin receptors on the hypothalamus,
thereby inhibiting SST release [8]. This mechanism has
been further corroborated in a study where 10 g of oral
melatonin provided to males elevated basal GH release
and GH responsiveness to GHRH at 60 and 120 min after
ingestion, while concomitantly inhibiting endogenous
SST release [9]. These data lend support to the contention
that melatonin supplementation increases the activity of
the SST receptor-effector system. Since exercise-induced
GH secretion is thought to be mediated predominantly
through a hypothalamic pathway, it seems likely that
melatonin facilitates GH secretion at a hypothalamic
level. Exogneous oral melatonin given at a dose of 5.0 mg
prior to bicycle exercise at 70% VO2max was shown to
cause significant increases in serum GH levels and those
of IGF binding protein-1 (IGFBP-1) when compared to
placebo [10]. However, 6.0 g of oral melatonin was
shown to have no effect on serum GH levels for 60 min
following a single bout of resistance exercise at 70%–85%
1-RM [11].
The primary purpose of this study was to determine the
effects of either a placebo or a melatonin supplement
administered at a dose of either 0.5 mg or 5.0 mg prior to
a single bout of heavy-resistance leg press exercise on free
GH, IGF-1, IGFBP-1, IGF binding protein-3 (IGFBP-3),
and SST levels in young men and women. A secondary
purpose was to assess the safety profiles of acute mela-
tonin supplementation by way of evaluating the systemic
hemodynamic effects and serum and whole blood clinical
markers in response to the three separate supplementa-
tion protocols.
Methods
Participants and screening
Sixty apparently healthy, resistance-trained (regular resist-
ance training at least twice weekly for at least one year)
males [n = 30 (22.72 ± 3.28 years, 180.94 ± 6.24 cm,
82.08 ± 9.18 kg)] and eumenorrheic females [n = 30
(21.90 ± 2.85 years, 165.91 ± 5.81 cm, 62.43 ± 8.50 kg)]
served as participants in the study. All participants were
cleared for participation by passing a mandatory medical
screening. Only participants considered as either low or
moderate risk and with no contraindications to exercise as
outlined by the American College of Sports Medicine
(ACSM) and/or who had not consumed any nutritional
supplements (excluding multi-vitamins) 2 months prior
to the study were allowed to participate. Additionally, par-
ticipants were not eligible if they had taken any over-the-
counter or prescription anti-inflammatory medication
within two weeks prior to the study. All eligible partici-
pants were asked to provide oral and informed written
consent based on university-approved documents and
approval was granted by the Institutional Review Board
for Human Subjects of Baylor University. Additionally, all
experimental procedures involved in the study conformed
to the ethical consideration of the Helsinki Code.Journal of the International Society of Sports Nutrition 2007, 4:14 http://www.jissn.com/content/4/1/14
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Entry/familiarization and baseline strength testing session
Participants believed to meet eligibility criteria were
invited to attend an entry/familiarization and baseline
strength testing session. Prior to this, participants were
instructed to refrain from lower-body resistance exercise
for 48 hours prior to baseline testing. Participants meeting
entry criteria were familiarized to the study protocol by
way of a verbal and written explanation outlining the
study design. Participants were then subjected to an initial
strength test to assess their one repetition maximum (1-
RM) on the leg press exercise (Nebula, Versailles, OH) to
be used in the study. Heart rate and blood pressure were
monitored throughout the strength testing session. Once
the 1-RM was determined, participants were asked to per-
form and practice the proposed resistance exercise session
in its entirety (see section for "Training and Supplementa-
tion") without blood sampling to familiarize them with
the protocol and to also insure that they were able to com-
plete the protocol before being formally admitted to the
study. At the conclusion of the entry/familiarization and
baseline strength testing session, each participant meeting
the eligibility criteria was given an appointment time one
week later to begin the study.
Resistance exercise protocol and supplementation
Male and female participants were matched by relative
strength levels (strength ÷ body weight) and then ran-
domly assigned to one of three different supplement pro-
tocols. For the supplement protocol, in a double-blind
fashion, groups received either 0.5 mg or 5.0 mg of N-
Acetyl-5-methoxytryptamine (melatonin) or 1.0 mg of a
dextrose placebo. Following the study protocol estab-
lished previously [10], each participant underwent a test-
ing session with a total duration of 180 minutes that
began at 2:00 pm. The participants were all provided with
a light breakfast at 8:00 am consisting of a meal replace-
ment bar (Premier Nutrition, Carlsbad, CA) containing 7
g of fat, 25 g of carbohydrate, 30 g of protein, and 280 kil-
ocalories, and were then required to fast until 2:00 pm.
Seventy-five minutes prior to each exercise session (12:30
pm), an intravenous cannula was inserted into a forearm
vein. Sixty minutes prior to the exercise session (-60), a
baseline blood sample was taken and then participants
orally received a placebo or melatonin supplement
(Iovate Health Sciences, Inc.) at a dosage or either 0.5 or
5.0 mg. During this 60-minute period of time, partici-
pants rested in a supine position and blood samples were
obtained every 15 minutes up to the initiation of the
resistance exercise trial (-45, -30, -15, 0). Using the resist-
ance exercise protocol previously established [3], partici-
pants performed the leg press exercise consisting of 7 sets
of 7 repetitions at 85% 1-RM; each set was performed over
the course of 30 seconds and followed by 150 seconds of
rest. As such, the resistance exercise session involved a
total duration of 20 minutes.
Heart rate and blood pressure were assessed during the
rest period between each set. A blood sample was
obtained 15 minutes following the completion of the
exercise session and at 15-minute intervals such that the
last blood sample was obtained at 120 minutes following
exercise (+15, +30, +45, +60, +75, +90, +105, +120).
Additionally, heart rate and blood pressure were assessed
at each blood sampling point. Each participant remained
recumbent and awake during the 120-minute post-exer-
cise period (see Figure 1 for an illustration of the experi-
ment protocol).
Dietary records
Food intake was not standardized prior to the study; how-
ever, participants were required to do a dietary recall for
the 48 hours prior to the resistance exercise session. The
48-hour dietary recalls were evaluated with the Food Proc-
essor dietary assessment software program (ESHA
An illustration of the experimental protocol used in the study Figure 1
An illustration of the experimental protocol used in the study.Journal of the International Society of Sports Nutrition 2007, 4:14 http://www.jissn.com/content/4/1/14
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Research, Salem, OR) to determine the average daily
macronutrient consumption of fat, carbohydrate, and
protein in the diet prior to supplementation and exercise.
Blood collection procedures
Venous blood samples were obtained into 10 ml vacu-
tainer tubes from a 20 gauge intravenous catheter inserted
into a forearm vein after the subcutaneous injection of a
topical anesthetic (2% Xylocaine). Following a five hour
fast, blood samples were obtained at 15-minute intervals
60 minutes prior to the resistance exercise session and
then at 15-minute intervals for 120 minutes following the
resistance exercise session. Blood samples were allowed to
stand for 10 minutes at room temperature and then cen-
trifuged at 2,400 rpm for 10 minutes. Serum was then sep-
arated and stored at -80°C until analysis.
Clinical chemistry analyses
Serum samples were analyzed for clinical chemistry mark-
ers (i.e., glucose, total protein, blood urea nitrogen, creat-
inine, BUN/creatinine ratio, AST, ALT, CK, LDH, GGT,
albumin, globulin, sodium, chloride, calcium, carbon
dioxide, total bilirubin, alkaline phosphatase, triglycer-
ides, cholesterol, HDL, LDL) using a Dade Dimension
RXL clinical chemistry analyzer (Dade-Behring Inc.,
Newark, DE). Whole blood samples were analyzed for
standard cell blood counts with percentage differentials
(i.e., hemoglobin, hematocrit, erythrocyte counts, MCV,
MCH, MCHC, RDW, leukocyte counts (neutrophils, lym-
phocytes, monocytes, eosinophils, basophils) using an
Cell-Dyn 3500 hematology analyzer (Abbott Laboratories
Inc., Pasadena, CA).
Serum hormone analyses
Using enzyme-linked immunoabsorbent assays (ELISA)
and enzyme-immunoabsorbent assays (EIA), serum sam-
ples were assayed for free GH, IGF-1, IGFBP-1, IGFBP-3,
(Diagnostics Systems Laboratories, Webster, TX), and SST
(Bachem, Torrance, CA) with a Wallac Victor-1420 micro-
plate reader (Perkin-Elmer Life Sciences, Boston, MA),
and the assays were performed in duplicate at a wave-
length or either 450 or 405 nm, respectively. For GH, an
ultra-sensitive assay with a sensitivity of 0.66 pg/ml was
used to determine the levels of free, unbound GH without
the detectable interference of circulating glycoproteins,
GH-dependent peptide hormones, or GHBP. For IGF-1,
an ultra-sensitive assay with a sensitivity of 0.015 ng/ml
was used to detect free IGF-1, with no cross-reactivity with
IGF-II or IGFBPs. The assays for IGFBP-1, IGFBP-3, and
SST had sensitivities of 0.25 ng/ml, 0.04 ng/ml, and 0.06
ng/ml, respectively. The average (± SD) coefficients of var-
iation for the duplicates of all samples performed for each
hormone were 6.65 ± 1.45%, 7.34 ± 1.67%, 7.12 ± 1.75%,
8.73 ± 2.02%, and 7.23 ± 2.85%, respectively, for GH,
IGF-1, IGFBP-1, IGFBP-3, and SST.
Assessment of hemodynamic safety markers (heart rate 
and blood pressure)
At each blood sampling period, participants underwent
the assessment of hemodynamic safety markers (heart rate
and blood pressure). Heart rate was determined by use of
a Polar heart rate monitor (Polar, San Ramon, CA), and
blood pressure was assessed in the supine position using
a mercurial sphygmomanometer using standard proce-
dures.
Statistical analyses
Statistical analyses were performed by utilizing separate 3
× 2 × 2 [Group (placebo, 0.5 mg, 5.0 mg] × Gender (male,
female) × Test (pre-exercise, post-exercise) factorial analy-
ses of variance (ANOVA) with repeated measures for each
criterion variable. Pair-wise comparisons were used to dif-
ferentiate significant differences among the three factors.
All statistical procedures were performed using SPSS 11.0
software and a probability level of < 0.05 was adopted
throughout.
Results
Resistance exercise session
The average intensity with which all the participants com-
pleted the exercise bout at the required 7 sets of 7 repeti-
tions was 84.7% ± 0.004 of the 1-RM, and it has been
shown that exercise at this intensity produces a GH
response [3,4].
Dietary analysis
Results showed that there were no significant differences
in total calories or the macronutritent intakes of carbohy-
drates, fats, and protein between the three groups in the
48 hours prior to the testing session (p > 0.05) (data not
shown).
Serum hormones
For very short half-life hormones that are highly sensitive
to diurnal variations, such as GH, we observed much var-
iability in the baseline levels even though the testing time
and food intake on each day was standardized. In addi-
tion, since we employed such a broad sampling window,
we also observed much variability throughout the pre-
and post-exercise periods. Therefore, peak serum hor-
mone responses before and after resistance exercise were
subtracted from the baseline values to determine delta
values. For standardization purposes, all serum hormones
were expressed in the same manner.
For GH, a significant Group × Gender × Test interaction
was observed (p = 0.012) indicating that both melatonin
supplements and resistance exercise was effective in ele-
vating serum GH levels, and that this response was more
pronounced in males. In males, pair-wise comparisons
revealed 5.0 mg melatonin to result in higher GH levelsJournal of the International Society of Sports Nutrition 2007, 4:14 http://www.jissn.com/content/4/1/14
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than placebo (p = 0.017) during the pre-exercise period
while a trend was evident suggesting 0.5 mg melatonin to
be greater than placebo (p = 0.077). During the post-exer-
cise period, both melatonin doses were greater than pla-
cebo (p = 0.042). In females, a trend existed in the post-
exercise period for the 0.5 mg supplement (p = 0.064)
(Figure 2).
For IGF-1, no significant Group × Gender × Test interac-
tion (p = 0.345) or main effects were noted for either gen-
der (p > 0.05) (Figure 3). For IGFBP-1, a significant Group
× Gender interaction was observed (p = 0.004) indicating
that the effects of supplementation on IGFBP-1 was differ-
ent between genders, but was not affected by resistance
exercise. Pair-wise comparisons showed that males exhib-
ited a greater response in IGFBP-1 than females (p =
0.022), and that the placebo (p = 0.034) and 0.5 mg mela-
tonin (p = 0.043) were greater than 5.0 mg melatonin
(Figure 4).
For IGFBP-3, a significant Group × Gender × Test interac-
tion was not observed (p = 0.412); however, for males a
main effect for Gender (p = 0.017) and Test (p = 0.028)
was observed and indicated that males demonstrated a
greater IGFBP-3 response than females. For males, pair-
wise comparisons showed that both 0.5 mg and 5.0 mg
melatonin was significantly greater than placebo in the
post-exercise period (see Figure 5).
For SST, a significant Group × Gender × Test interaction
was observed (p = 0.036) indicating that both melatonin
supplements and resistance exercise was effective in ele-
vating serum GH levels, and that this response was more
pronounced in males. In males, pair-wise comparisons
revealed 5.0 mg melatonin to result in lower SST levels
than placebo (p = 0.031) during the pre-exercise period
while a trend was evident suggesting 0.5 mg melatonin to
be greater than placebo (p = 0.082, effect size = 0.029).
During the post-exercise period, both melatonin doses
were less than placebo (p = 0.046), but not different from
one another. In females, a trend existed in the pre-exercise
period for the 5.0 mg supplement (p = 0.078) (Figure 6).
Hemodynamic and clinical chemistry analyses
Results showed no significant abnormal effects on either
hemodynamic or clinical chemistry variables between
groups as a result of either the supplementation or the
resistance exercise (p > 0.05) (Tables 1, 2, 3).
Discussion
For some of the hormones, GH in particular, we observed
much variability in the baseline values, even though the
participants were fasted and reported for testing at the
same time of day. Even though melatonin plays a role in
modulating circadian rhythm patterns and GH is subject
to diurnal variations, we standardized daily testing so that
it was the same for all participants and followed previ-
ously-established guidelines [10-12]. Therefore, we are
confident that the testing protocol was not a confounder
of our results.
In males, 5.0 mg melatonin resulted in the greatest
increase in serum GH during the pre-exercise period
(157% increase from baseline), whereas in the post-exer-
cise period both 0.5 mg (106% increase from baseline)
and 5.0 mg (132% increase from baseline) melatonin
effectively increased GH compared to placebo. Interest-
ingly, during the pre-exercise period, we observed average
Free GH for males (A) and females (B) expressed as the delta values for the peak changes pre- and post-exercise relative to  baseline values Figure 2
Free GH for males (A) and females (B) expressed as the delta values for the peak changes pre- and post-exercise relative to 
baseline values. * Significantly different from placebo (p < 0.05). † Significantly different from the corresponding values for 
females (p < 0.05).Journal of the International Society of Sports Nutrition 2007, 4:14 http://www.jissn.com/content/4/1/14
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(± SD) peak GH values to occur at 45 ± 4.5 and 40 ± 3.2
minutes, respectively, for the 0.5 mg and 5.0 mg groups.
However, during the post-exercise period, we observed
average peak GH values to occur at 25 ± 2.8 and 23 ± 2.2
minutes, respectively, for the 0.5 mg and 5.0 mg groups
(Figure 2). Our GH results are not consistent with other
data [10,13] that showed significant increases in GH in
males with all melatonin doses. While Forsling et al. [13]
did not involve an exercise bout, Meeking et al. [10]
employed cycling exercise for 8 min at 70% of VO2max,
and showed an increase in GH levels with 5.0 mg of mela-
tonin when compared to placebo. More recently, how-
ever, 6 mg of oral melatonin in conjunction with a total-
body resistance exercise bout involving 10 exercises, 25
total sets, and relative intensities of either 70% or 80% 1-
RM was shown to have no effect in increasing in serum
GH levels when compared to placebo [11].
Even though the present study was similar in design to a
previous study [10], that reported no significant difference
in GH levels between groups in the first 60 minutes fol-
lowing supplementation, our results for 5.0 mg melatonin
suggest the contrary. However, it should be noted that
unlike most studies, we measured free GH using an ultra-
IGFBP-1 for males (A) and females (B) expressed as the delta values for the peak changes pre- and post-exercise relative to  baseline values Figure 4
IGFBP-1 for males (A) and females (B) expressed as the delta values for the peak changes pre- and post-exercise relative to 
baseline values. ‡ Significantly different from each corresponding value in females (p < 0.05).
IGF-1 for males (A) and females (B) expressed as the delta values for the peak changes pre- and post-exercise relative to base- line values Figure 3
IGF-1 for males (A) and females (B) expressed as the delta values for the peak changes pre- and post-exercise relative to base-
line values. There were no significant differences located for IGF-1 (p > 0.05).Journal of the International Society of Sports Nutrition 2007, 4:14 http://www.jissn.com/content/4/1/14
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sensitive ELISA method in an effort to determine the levels
of free, unbound GH without the detectable interference
of circulating glycoproteins, GH-dependent peptide hor-
mones, or GHBPs. Almost 50% of GH in circulation is
bound to high affinity GHBPs, and circulating GHBP lev-
els reflect the tissue GH receptor status due to the fact that
GHBP arises from proteolytic cleavage of the extracellular
domain of the GH receptor [14]. The fraction of bound
GH decreases at or above a GH concentration in the mid-
dle of the physiological range [15], and acute resistance
exercise has been shown to have no effect of the levels of
serum GHBP [16]. As such, it is only the free, unbound
GH which is able to bind to the extracellular domain of
the GH receptor. Therefore, the determination of free GH
is a much better representation of GH bio-availability
resulting from melatonin supplementation and resistance
exercise, and our results suggest both melatonin doses to
increase free GH levels, particularly in males.
For GH in females, however, the response to melatonin
supplementation was dissimilar to the response observed
in males. While 0.5 mg melatonin was modestly increased
during the post-exercise period (30% increase from base-
line), the greatest increase in serum GH during both the
SST for males (A) and females (B) expressed as the delta values for the peak changes pre- and post-exercise relative to baseline  values Figure 6
SST for males (A) and females (B) expressed as the delta values for the peak changes pre- and post-exercise relative to baseline 
values. * Significantly different from placebo (p < 0.05). † Significantly different from the corresponding values for females (p < 
0.05).
IGFBP-3 for males and females expressed as the delta values for the peak changes pre- and post-exercise relative to baseline  values Figure 5
IGFBP-3 for males and females expressed as the delta values for the peak changes pre- and post-exercise relative to baseline 
values. * Significantly different from placebo (p < 0.05).Journal of the International Society of Sports Nutrition 2007, 4:14 http://www.jissn.com/content/4/1/14
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pre- and post-exercise periods occurred in the placebo
group (see Figure 2). While there are data demonstrating
a significant increase in serum GH after an acute bout of
resistance exercise in females, the increase was less than
that observed in males [17].
As there have been few studies investigating the effects of
oral melatonin in females, our present results are difficult
to interpret. In the present study, we did not control for
menstrual cycle activity; therefore, it is possible that the
point of the 28-day menstrual cycle at which each female
was tested could have led to the observed differences in
serum GH. There are data demonstrating increases in
serum GH levels from mid-cycle onward, despite only
modest elevations in serum IGF-1, suggesting a lower sen-
sitivity to GH in women [18]. The presence of gender dif-
ferences in the GH/IGF-1 axis appears to be due to the
level of endogenous estradiol, and suggests that estradiol
affects GH action at the level of the GH receptor expres-
sion and function [19]. Women typically have higher
mean 24-h GH levels than men as a result of greater GH
secretory burst mass and a higher degree of disordered GH
release [20], which may likely explain the higher GH lev-
els in the placebo group in females, compared to males
(Figure 1). However, it has been shown that for any given
body surface area, the rate of disappearance of GH once in
circulation reflect predominately the time mode of GH
entry, rather than gender, menstrual cycle state, or prevail-
ing estradiol concentration [21]. Therefore, while it is pos-
sible that females have a differential estradiol-induced
responsiveness in GH release, it is unlikely that menstrual
cycle activity (and our lack of control of it in the present
study) played a role in our results.
In both males and females, serum free IGF-1 levels did not
significantly increase in response to melatonin supple-
mentation or resistance exercise and there were no signif-
icant differences between supplements (Figure 3). Dall et
al. [22] observed no changes in free IGF-1 following a
maximal treadmill test lasting seven min in duration.
While any increases in serum GH are short-lived, the sub-
sequent GH-mediated hepatic IGF-1 release in response to
resistance exercise may take anywhere from 8–30 hours,
and any immediate increase in serum IGF-1 levels is typi-
cally due to its release from disrupted cells already con-
taining IGF-1 [23]. A high-intensity bout of resistance
exercise in men was shown to significantly increase serum
GH; however, this response did not appear to affect IGF-1
levels after a 24-h recovery period [24].
Relative to IGFBP-1, our results support those of Meeking
et al. [10] and we observed no significant increase in
response to melatonin supplementation or resistance
exercise for both males and females (Figure 4). IGFBP-1,
which is thought to be a direct regulator of free IGF-1,
increases during states of catabolism [25]. As such, the lev-
els of IGFBP-1 seem to be unresponsive to exercise less
than 30 min in duration, whereas longer duration exercise
significantly increases IGFBP-1 [26]. IGFBP-1 appears to
be associated with basal GH secretion rate [27], and has
also been shown to be down-regulated by circulating
insulin [28] and GH levels [29]. Even though we did not
measure insulin in this study we measured serum glucose
levels with our serum clinical chemistry panel and discov-
ered that there were no significant changes between sup-
plements throughout the testing session. Furthermore,
Meeking et al. [10] also showed no significant difference
between groups for serum insulin or glucose. Therefore,
our observations can allow us to safely assume that there
was likely not a significant insulin response and hence no
change in IGFBP-1 that may have otherwise been medi-
ated by melatonin supplementation or resistance exercise.
For males, 0.5 mg and 5.0 mg melatonin resulted in nota-
ble increases in serum IGFBP-3 during both the pre- (0.5
mg and 5.0 mg = 8% and 6% increases from baseline,
respectively) and post-exercise periods (0.5 mg and 5.0
mg = 11% and 9% increases from baseline, respectively)
that were not significant from each other or placebo.
Although not significant, levels were even greater during
the post-exercise period suggesting IGFBP-3 to be respon-
sive to resistance exercise. In females, modest increases in
IGFBP-3 were observed in all three supplements during
the pre-exercise period, with the placebo and 5.0 mg
melatonin groups exhibiting further increases during the
post-exercise period (see Figure 5). Since IGFBP-3
increases concomitant with GH, for males our data por-
tray this trend in both the 0.5 mg and 5.0 mg melatonin
Table 1: Hemodynamic Clinical Safety Markers
Time 0.5 mg Placebo 5.0 mg
-60 0 15 120 -60 0 15 120 -60 0 15 120
Heart Rate (bpm) 67 ±11.9     67 ±10.7 84 ±9.9  63 ±8.0 59 ±10.6             60 ±8.4 77 ±9.2 61 ±10.5   68 ±10.1      64 ±8.4 78 ±9.4         60 ±7.2
SBP (mmHg) 114 ±7.8         111 ±5.8 118 ±10.6  110 ±10.4 114 ±6.4 114 ±7.9 115 ±7.6 111 ±8.1  110 ±7.4 113 ±8.3 117 ±6.9   112 ±8.4
DBP (mmHg) 77 ±4.8 70 ±6.7 73 ±7.0  69 ±11.9 70 ±5.6 72 ±8.2 73 ±6.4 73 ±9.5 76 ±4.7 76 ±5.8 78 ±7.3 73 ±6.3
Data are presented as means ± SD. Results showed no significant differences between groups as a result of either the supplementation or the 
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Table 2: Serum Clinical Chemistry Markers
Time 0.5 mg Placebo 5.0 mg
-60 0 15 120 -60 0 15 120 -60 0 15 120
Triglyceride (mg/dl) 75±22       67±16 63±12     63±13 76±28            76±25    76±30             83±37   83±32         80±42        74±38        70±34
Cholesterol (mg/dl) 160±28    164±30 164±35  168±36 167±24        167±38   160±34       165±37   156±20       152±19        160±22      167±28
HDL (mg/dl) 49±10     49±11  51±10 51±11 54±13             53±16  53±14        53±15  56±18        52±13        57±19          60±17
LDL (mg/dl) 95±27   95±27 96±29 98±31 97±16           98±23     94±20        96±22   82±15        84±15                84±16 88±21 
GGT  (U/L) 23±5.1      22±5.3 23±4.1 22±4.9 25±6.9                                 26±7.7    25±7.5  24±7.5  25±5.3 25±5.9  25±4.5 25±5.8
LDH (U/L) 231±134   150±51 200±188 121±16 168±51        181±81 266±283  210±83   191±108   218±263  139±22 131±15    
Uric Acid (g/dl) 4.7±.71               4.8±.74  5.2±.73 5.6±.80 5.5±.88        5.3±.83   5.1±2.0 5.8±1.2   5.3±.88    5.2±.96   5.5±.87       5.7±.93 
Glucose (mg/dl) 99±51               99±48    98±38     92±27 98±22       92±13     89±5.3   89±6.9     87±9.4   85±6.6   88±9.4    87±9.5
BUN (mg/dl) 15±4.8             15±4.9  15±4.1      14±4.2 15±3.9     15±4.0     14±3.5       13±2.9  16±4.8       16±4.3   15±4.6  15±3.3
Creatinine (mg/dl) 1.1±.20         1.2±.23   1.3±.29      1.2±.20 1.0±.13    1.1±.23 1.2±.21   1.1±.22  1.1±.21  1.1±.13  1.3±.17 1.1±.17
Calcium (mg/dl) 9.2±.29              9.4±.37  9.5±.41  9.6±.30 9.4±.39                           9.4±.37   9.6±.45   9.6±.60 9.2±.70  9.4±.54   9.6±.52 9.6±.64 
Total Protein (g/dl) 7.3±.34      7.3±.36    7.5±.46  7.4±.51 7.6±.42    7.6±.37 7.6±.61   7.5±.61  7.2±.45 7.3±.61  7.3±.48 7.4±.51
Albumin (g/dl) 4.6±.27             4.7±.30    4.7±.29 4.8±.27 4.8±.34     4.8±.31 4.7±.36 4.8±.38    4.6±.33  4.6±.27  4.6±.43 4.7±.39
Total Bilirubin (mg/dl) .77±.25              .75±.25  .79±.28 .84±.32 .68±.24   .67±.21   .74±.25 .82±.27 .78±.42 .74±.47 .74±.46 .83±.47
ALP (U/L) 76±18        76±16 76±16 77±13 79±16        74±16    74±21 75±19 69±14 74±18  71±12 71±14
AST (U/L) 32±16     23±9 27±20  20±7 31±16        34±17  38±22 37±16 28±12  21±6.7  22±5.1 21±5.7 
ALT (U/L) 26±4.7     25±4.1  26±4.7   25±5.1 28±12       30±16      30±16  28±15 27±9.8 27±11 27±9.4 28±9.3
CK (U/L) 253±273               231±257 259±298 250±253 273±363   286±370  281±351 262±326   173±105  177±109 182±102  179±101
Data are presented as means ± SD. Results showed no significant differences between groups as a result of either the supplementation or the resistance exercise (p > 0.05).J
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Table 3: Whole Blood Clinical Chemistry Markers
Time 0.5 mg Placebo 5.0 mg
-60 0 15 120 -60 0 15 120 -60 0 15 120
WBC (cells/µl) 5.4±.84       5.4±1.1        6.3±2.1       7.2±1.8   4.5±.98       4.5±.84       5.7±2.0        6.0±1.1   6.1±2.3       6.1±2.4       6.4±2.4       7.0±2.8
RBC (cells/µl) 5.0±.26       5.0±.31        5.1±.17       5.0±.25   4.7±.43       4.7±.31        4.8±.27       4.7±.31   4.9±.28       4.8±.41       4.9±.33       4.8±.37
Hemoglobin (g/dl) 15±.60        15±.69        15±.35           15±.53   14±1.4        14±.80        14±.74        14±.96   15±.74        14±1.0        15±.78        14±.89
Hematocrit (%) 45±1.7       44±2.0         45±.97        44±1.7   42±4.2        42±2.4        43±2.0        42±2.2   43±1.9        42±3.0        43±2.4        42±2.7
MCV (fL) 89±2.1        89±2.0          89±2.1        89±2.1   89±3.0        89±3.1        89±3.4        89±3.2   88±1.7        89±1.7        88±1.5        88±1.7
MCH (pg/cell) 30±.78       30±.89           30±.72        30±.72   30±1.2        30±1.5        30±1.2        30±1.4   30±.60        30±.51        30±.70        30±.70
MCHC (g/dl) 34±.35       34±.33          34±.33         34±.50   34±.44        34±1.1        34±.55        34±.97   34±.70        34±.41        34±.56        34±.69
Neutrophils (cells/µl) 3.1±.59      3.3±.78        3.9±1.1         5.1±1.7   2.3±.79       2.3±.73      3.9±2.0       4.1±1.3   3.7±2.0       3.9±2.0       4.2±1.9      4.8±2.4
Lymphocyte (cells/µl) 1.6±.38      1.8±.83        2.1±1.3       2.1±1.8      1.8±.66       1.4±.19      1.2±.18         1.4±.33   1.6±.48       1.5±.41       1.6±.51      1.6±.47
Monocytes (cells/µl) .43±.10      .41±.09        .45±.18      .47±.17   .32±.11     .33±.10       .35±.09      .39±.13   .50±.19      .48±.20       .49±.21      .51±.20
Eosinophils (cells/µl) .21±.12     .18±.11         .17±.11       .14±.12   .14±.07      .12±.06       .10±.05       .09±.06   .19±.16     .19±.16       .17±.14     .13±.12
Basophils (cells/µl) .06±.01     .07±.03        .07±.03       .06±.02   .06±.02      .06±.02       .06±.02       .06±.02   .08±.02      .06±.01       .06±.02      .07±.02
Data are presented as means ± SD. Results showed no significant differences between groups as a result of either the supplementation or the resistance exercise (p > 0.05).Journal of the International Society of Sports Nutrition 2007, 4:14 http://www.jissn.com/content/4/1/14
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doses. Previous studies have shown increases in IGFBP-3
following acute maximal exercise with protocols involv-
ing a treadmill [22] and cycle ergometer [30]. IGFBP-3 is
primarily involved in transporting most (>75%) circulat-
ing IGF-1 to the muscle where it binds to the IGF-1 recep-
tor [31]. The proteolytic activity of IGFBP-3 may be a
potent regulator of IGF-1 bioactivity [32], and increases in
IGFBP-3 proteolysis would release bound IGF-1 thereby
increasing the circulating levels of free IGF-1. It has been
suggested that increases in IGFBP-3 are correlated with
IGFBP-3 proteolysis; however, Schwarz et al. [30] demon-
strated that IGFBP-3 proteolytic activity was not affected
by an acute bout of maximal cycling exercise. In the
present study, we observed increases in IGFBP-3 but no
increases in free IGF-1, suggesting no proteolytic activity
of IGFBP-3. Therefore, based on our results this could
indicate a possible mechanism by which melatonin insti-
gates elevations in IGFBP-3 release that are not associated
with IGFBP-3 proteolysis and the subsequent release of
bound IGF-1.
In males, 5.0 mg melatonin resulted in the greatest
decrease in serum SST during the pre-exercise period
(164% increase from baseline) while 0.5 mg melatonin
decreased 70% from baseline, whereas in the post-exercise
period both 0.5 mg (44% decrease from baseline) and 5.0
mg (76% decrease from baseline) melatonin effectively
decreased SST compared to placebo. Interestingly, during
the pre-exercise period, we observed average (± SD) peak
decreases in SST values to occur at 28 ± 5.7 and 33 ± 6.4
minutes, respectively, for the 0.5 mg and 5.0 mg groups.
However, during the post-exercise period, we observed
average peak decreases in SST values to occur at 14 ± 3.6
and 19 ± 4.2 minutes, respectively, for the 0.5 mg and 5.0
mg groups (Figure 6).
For SST in females, the response to melatonin supplemen-
tation was similar to the response observed in males; how-
ever, the magnitude of the response was significantly less.
During the pre-exercise period, 0.5 and 5.0 mg melatonin
were decreased 35% and 47%, respectively, from baseline.
While 5.0 mg melatonin was modestly decreased during
the post-exercise period (32% increase from baseline), 0.5
mg melatonin only decreased 14% from baseline (Figure
6).
Based on the pre-exercises responses in serum GH for
males for 5.0 mg melatonin, our data support the conten-
tion that melatonin increases serum GH levels due to an
apparent inhibition of SST. However, the post-exercise
responses for serum GH were greater with 0.5 mg mela-
tonin while SST was less than during the pre-exercise
period, which suggest the potential interactive effects of
resistance exercise. The underlying mechanisms for exer-
cise-induced increases in GH are not well known. Many
factors such as the mode, duration, and intensity of exer-
cise, age, gender, body composition, and nutritional and
training status may modulate increases in GH [33]. In the
present study, we controlled for all of these afore-men-
tioned variables in such a way that our results are prima-
rily contingent on the melatonin supplement and/or
resistance exercise. The increase in GH release in response
to sub-maximal exercise is mainly mediated by an
increased central cholinergic tone [34], which reduces the
activity of hypothalamic SST. Increased GH release from
high-intensity exercise, however, appears to likely be
potentiated from the partial inhibition of SST as well as
the concomitant activation of endogenous GHRH [35].
Based on the observed patterns of response from the 0.5
mg and 5.0 mg melatonin doses in the post-exercise
period, this scenario is conceivable.
For hemodynamic and serum and whole blood clinical
safety markers, none of the variables measured were
shown to be changed throughout the course of the testing
session for all three supplements (Tables 1, 2, 3). There-
fore, within the confines of the experimental design, our
data suggests that melatonin is safe to supplement orally
based on the hemodynamic safety markers, and the serum
and whole blood clinical chemistry markers we assessed.
In addition, there were also no adverse side effects from
ingesting the melatonin supplements reported by the sub-
jects immediately following the testing session.
In conclusion, for males 5.0 mg melatonin appears to
increase serum GH while concomitantly lowering SST lev-
els; however, when combined with resistance exercise
both 0.5 mg and 5.0 mg melatonin appears to positively
impact GH levels in a manner not entirely dependent on
decreases in SST. Relative to the response in females, it
appears that both melatonin and resistance exercise elicits
a greater GH response in males.
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